0 items

in your cart

  • Search for Medications
  • Viewcart | Checkout
  • Manage Account
  • Click-to-Call  

Prescription Drug Search

Product Request Form

Rindopepimut is currently not available.

Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Rindopepimut becomes available, please fill out the form below.


*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!

Search for a drug:


Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about SaveRxCanada.to

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Rindopepimut:

  • Albania
  • Algeria
  • Argentina
  • Belarus
  • Belize
  • Bosnia and Herzegovina
  • Chile
  • Croatia
  • Cuba
  • Czech Republic
  • Dominican Republic
  • Ecuador
  • Egypt
  • Finland
  • Germany
  • Greenland
  • Guadeloupe
  • Honduras
  • Hungary
  • India
  • Iran
  • Jamaica
  • Korea, South
  • Liechtenstein
  • Lithuania
  • Morocco
  • Netherlands Antilles
  • Paraguay
  • Peru
  • Philippines
  • Portugal
  • Qatar
  • Romania
  • Switzerland
  • Taiwan
  • Ukraine
  • United Kingdom, UK
  • United States, US
  • Uruguay
  • Uzbekistan
View All Countries

Latest news releases on Rindopepimut:

Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.

Rindopepimut - Wikipedia

Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.

Pipeline | Celldex Therapeutics

Learn about the targeted therapeutics being developed by Celldex Therapeutics.

Press Releases | Celldex Therapeutics

Press Releases. Year: Search: All Releases. Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors Nov 30, 2017 15.4 KB ...

Rindopepimut Misses OS Endpoint in Phase III Glioblastoma ...

Treatment with rindopepimut (Rintega) plus temozolomide failed to improve overall survival compared with temozolomide and a control for patients with newly diagnosed ...

PubMed - National Center for Biotechnology Information

Moved Permanently. The document has moved here.

Celldex's Rindopepimut (Rintega(R)) Receives FDA ...

Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma

Rindopepimut - DrugBank

Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The ...

Phase III Study of Rindopepimut/GM-CSF in Patients With ...

This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to ...

Rindopepimut ® : A promising immunotherapeutic for the ...

Rindopepimut ®: A promising immunotherapeutic for the treatment of glioblastoma multiforme. AM Swartz, QJ Li, and JH Sampson, MD, PhD ... Rindopepimut ® is emerging ...

Customer Service
1-866-799-3435 | Contact Form
Copyright © 2018 SaveRxCanada.to All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK